JP2019038829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019038829A5 JP2019038829A5 JP2018202024A JP2018202024A JP2019038829A5 JP 2019038829 A5 JP2019038829 A5 JP 2019038829A5 JP 2018202024 A JP2018202024 A JP 2018202024A JP 2018202024 A JP2018202024 A JP 2018202024A JP 2019038829 A5 JP2019038829 A5 JP 2019038829A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- formula
- compound
- disease
- neurodegenerative disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 14
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000027747 Kennedy disease Diseases 0.000 claims 4
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- -1 purine skeleton compound Chemical class 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- UYODNJZBUUEXPC-UHFFFAOYSA-N 9-[2-(2,2-dimethylpropylamino)ethyl]-8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]purin-6-amine Chemical compound N1=CN=C2N(CCNCC(C)(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N UYODNJZBUUEXPC-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80642706P | 2006-06-30 | 2006-06-30 | |
| US60/806,427 | 2006-06-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017110721A Division JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019038829A JP2019038829A (ja) | 2019-03-14 |
| JP2019038829A5 true JP2019038829A5 (https=) | 2019-05-09 |
| JP6585266B2 JP6585266B2 (ja) | 2019-10-02 |
Family
ID=38895418
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518602A Expired - Fee Related JP5599610B2 (ja) | 2006-06-30 | 2007-07-02 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2013058040A Expired - Fee Related JP5824698B2 (ja) | 2006-06-30 | 2013-03-21 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2015174609A Pending JP2016028063A (ja) | 2006-06-30 | 2015-09-04 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2017110721A Expired - Fee Related JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2018202024A Expired - Fee Related JP6585266B2 (ja) | 2006-06-30 | 2018-10-26 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518602A Expired - Fee Related JP5599610B2 (ja) | 2006-06-30 | 2007-07-02 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2013058040A Expired - Fee Related JP5824698B2 (ja) | 2006-06-30 | 2013-03-21 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2015174609A Pending JP2016028063A (ja) | 2006-06-30 | 2015-09-04 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP2017110721A Expired - Fee Related JP6427227B2 (ja) | 2006-06-30 | 2017-06-05 | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10336757B2 (https=) |
| EP (2) | EP3305297A1 (https=) |
| JP (5) | JP5599610B2 (https=) |
| AU (1) | AU2007269144B2 (https=) |
| CA (1) | CA2656202C (https=) |
| DK (1) | DK2034839T3 (https=) |
| ES (1) | ES2645095T3 (https=) |
| WO (1) | WO2008005937A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2007134298A2 (en) * | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| US10336757B2 (en) * | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| JP5401329B2 (ja) | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| CA2705579A1 (en) * | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| US20090258869A1 (en) * | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| AU2009262670B2 (en) | 2008-06-26 | 2013-06-20 | Zevra Denmark A/S | Use of Hsp70 as a regulator of enzymatic activity |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| AU2013204109B2 (en) * | 2009-10-07 | 2016-05-05 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| CA2817773A1 (en) | 2010-11-30 | 2012-06-07 | Orphazyme Aps | Methods for increasing intracellular activity of hsp70 |
| ES2647889T3 (es) * | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| WO2012138894A1 (en) | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| DK2729806T3 (en) * | 2011-07-08 | 2017-05-15 | Sloan-Kettering Inst For Cancer Res | APPLICATIONS OF MARKED HSP90 INHIBITORS |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP2879675B1 (en) * | 2012-08-06 | 2019-11-13 | Duke University | Compounds and methods for targeting hsp90 |
| MA38287B1 (fr) | 2013-01-23 | 2018-08-31 | Astrazeneca Ab | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| JP6539275B2 (ja) | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
| EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| WO2015116774A1 (en) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| AU2015224576A1 (en) | 2014-03-03 | 2016-09-22 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015143004A1 (en) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| AU2015317447B2 (en) | 2014-09-15 | 2021-02-25 | Zevra Denmark A/S | Arimoclomol formulation |
| CN113521314A (zh) | 2014-09-17 | 2021-10-22 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| WO2017062520A1 (en) | 2015-10-05 | 2017-04-13 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| DK3782624T3 (da) | 2016-04-29 | 2025-12-15 | Zevra Denmark As | Arimoclomol til behandling af glucocerebrosidase-associerede lidelser |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| SG10201913562VA (en) * | 2017-04-24 | 2020-03-30 | Samus Therapeutics Inc | Hsp90 inhibitor oral formulations and related methods |
| CN110799194A (zh) | 2017-06-20 | 2020-02-14 | 马德里加尔制药公司 | 包含靶向治疗剂的联合疗法 |
| EP3641647A4 (en) | 2017-06-20 | 2021-05-05 | Madrigal Pharmaceuticals, Inc. | TARGETED THERAPEUTICS |
| KR20200019220A (ko) * | 2017-06-23 | 2020-02-21 | 사무스 테라퓨틱스, 인코포레이티드 | 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| KR20230128462A (ko) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| WO2000061578A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| JP2005519848A (ja) | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０に結合するための小分子組成物 |
| EP1387678A1 (en) * | 2001-05-03 | 2004-02-11 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| JP2005524661A (ja) | 2002-02-28 | 2005-08-18 | アストラゼネカ アクチボラグ | ３−シクリル−５−（窒素含有５員環）メチル−オキサゾリジノン誘導体と抗菌剤としてのその使用 |
| WO2004094647A2 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| WO2005012482A2 (en) | 2003-06-30 | 2005-02-10 | Sloan-Kettering Institute For Cancer Research | Assay for identification of bioactive compounds that interact with heat shock protein 90 |
| KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| MX2007010227A (es) | 2005-02-25 | 2007-11-07 | Serenex Inc | Derivados de tetrahidroindolona y tetrahidroindazolona. |
| WO2006130469A1 (en) * | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
| WO2007117466A2 (en) | 2006-03-31 | 2007-10-18 | Massachusetts Institute Of Technology | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| US20100204093A1 (en) | 2006-07-27 | 2010-08-12 | University Of Florida Research Foundation, Inc | Use of heat shock activators for tissue regeneration |
| EP2061772A4 (en) | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| US8580519B2 (en) | 2006-11-27 | 2013-11-12 | University Of Maryland, Baltimore | Use of plasma HSP90 related to malignancy |
| JP5401329B2 (ja) | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| EP2183221A1 (en) | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CA2705579A1 (en) | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| ES2647889T3 (es) | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| WO2012138894A1 (en) | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| JP6539275B2 (ja) | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
-
2007
- 2007-07-02 US US12/307,063 patent/US10336757B2/en active Active
- 2007-07-02 WO PCT/US2007/072671 patent/WO2008005937A2/en not_active Ceased
- 2007-07-02 EP EP17177927.5A patent/EP3305297A1/en not_active Withdrawn
- 2007-07-02 DK DK07812557.2T patent/DK2034839T3/en active
- 2007-07-02 CA CA2656202A patent/CA2656202C/en active Active
- 2007-07-02 EP EP07812557.2A patent/EP2034839B1/en active Active
- 2007-07-02 AU AU2007269144A patent/AU2007269144B2/en not_active Ceased
- 2007-07-02 ES ES07812557.2T patent/ES2645095T3/es active Active
- 2007-07-02 JP JP2009518602A patent/JP5599610B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-21 JP JP2013058040A patent/JP5824698B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-10 US US14/482,628 patent/US20140378452A1/en not_active Abandoned
-
2015
- 2015-09-04 JP JP2015174609A patent/JP2016028063A/ja active Pending
-
2017
- 2017-06-05 JP JP2017110721A patent/JP6427227B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-26 JP JP2018202024A patent/JP6585266B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-30 US US16/398,650 patent/US20190389864A1/en not_active Abandoned
-
2021
- 2021-10-15 US US17/502,563 patent/US20230060990A1/en not_active Abandoned
-
2023
- 2023-05-26 US US18/202,704 patent/US12473288B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019038829A5 (https=) | ||
| JP2019524822A5 (https=) | ||
| JP2018150331A5 (https=) | ||
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| MY180575A (en) | Cyclopropanamine compound and use thereof | |
| JP2014500861A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2016534063A5 (https=) | ||
| JP2019516739A5 (https=) | ||
| JP2006526031A5 (https=) | ||
| JP2012255002A5 (https=) | ||
| JP2009504748A5 (https=) | ||
| JP2020502047A5 (https=) | ||
| JP2016537338A5 (https=) | ||
| MX2011011477A (es) | Derivados de isoxazol-piridazina. | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| JP2019529514A5 (https=) | ||
| JP2010522711A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| JP2011046708A5 (https=) | ||
| JP2019151627A5 (https=) | ||
| JP2017505811A5 (https=) | ||
| JP2010500284A5 (https=) | ||
| JP2019536778A5 (https=) |